BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 30320878)

  • 1. During acute graft versus host disease CD28 deletion in donor CD8
    Uri A; Lühder F; Kerkau T; Beyersdorf N
    Eur J Immunol; 2018 Dec; 48(12):2055-2067. PubMed ID: 30320878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.
    Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA
    J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.
    Yang YG; Qi J; Wang MG; Sykes M
    Blood; 2002 Jun; 99(11):4207-15. PubMed ID: 12010827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy.
    Park HB; Lee JE; Oh YM; Lee SJ; Eom HS; Choi K
    Exp Mol Med; 2017 Jul; 49(7):e360. PubMed ID: 28751785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
    Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
    Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro polyclonal activation of conventional T cells with a CD28 superagonist protects mice from acute graft versus host disease.
    Beyersdorf N; Werner S; Wolf N; Hünig T; Kerkau T
    Eur J Immunol; 2015 Jul; 45(7):1997-2007. PubMed ID: 25907100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.
    Chakraverty R; Eom HS; Sachs J; Buchli J; Cotter P; Hsu R; Zhao G; Sykes M
    Blood; 2006 Sep; 108(6):2106-13. PubMed ID: 16757687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
    Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.
    Wu T; Young JS; Johnston H; Ni X; Deng R; Racine J; Wang M; Wang A; Todorov I; Wang J; Zeng D
    J Immunol; 2013 Jul; 191(1):488-99. PubMed ID: 23709681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.
    Zheng H; Matte-Martone C; Li H; Anderson BE; Venketesan S; Sheng Tan H; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Feb; 111(4):2476-84. PubMed ID: 18045967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).
    Taylor PA; Panoskaltsis-Mortari A; Freeman GJ; Sharpe AH; Noelle RJ; Rudensky AY; Mak TW; Serody JS; Blazar BR
    Blood; 2005 Apr; 105(8):3372-80. PubMed ID: 15618467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of bone marrow mesenchymal stem cells on acute graft versus host disease and graft versus leukemia after allogeneic bone marrow transplantation].
    Hu WB; Gao QP; Chen YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):404-7. PubMed ID: 15972130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.
    Drobyski WR; Gendelman M; Vodanovic-Jankovic S; Gorski J
    J Immunol; 2003 Mar; 170(6):3046-53. PubMed ID: 12626559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
    Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
    J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism.
    Mapara MY; Kim YM; Marx J; Sykes M
    Transplantation; 2003 Jul; 76(2):297-305. PubMed ID: 12883182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.